Document |
Document Title |
WO/2023/063701A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
WO/2023/062575A1 |
Disclosed herein are certain succinamido derivatives of Formula (I): (I) that inhibit Wemer Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are thereofore useful in treating c...
|
WO/2023/058673A1 |
The present disclosure provides: a sulfur-containing compound which has a predetermined structure and is useful for treating or preventing eye diseases such as presbyopia and cataracts; and an agent for treating or preventing eye disease...
|
WO/2022/187804A9 |
Compounds which are benzoxazolone derivatives are disclosed, including compounds of the following genus: The compounds possess anti-inflammasome properties and exhibit anti-fibrotic and anti-proliferative effects. They are useful in inhi...
|
WO/2023/059605A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
|
WO/2023/059899A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
WO/2023/051761A1 |
Provided are a substituted heteroaryl phthalazine derivative as shown in formula (I-0), a use thereof as an NLRP3 inhibitor, and a preparation method therefor; the derivative has relatively good NLRP3 inhibitory activity.
|
WO/2023/051134A1 |
The present invention relates to an organometallic iridium compound and an application thereof. The organometallic iridium compound has a general formula of Ir(La)(Lb)(Lc), wherein La has the structure as shown in formula (1), and Lb has...
|
WO/2023/054715A1 |
The present invention provides a method for producing a compound through a cross-coupling reaction, wherein: the method for producing a compound includes reacting a compound 1 having a leaving group X1 on a carbon atom of an aromatic rin...
|
WO/2023/055177A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
WO/2023/052354A1 |
The present disclosure relates to the compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically accep...
|
WO/2023/048118A1 |
A purpose of the present invention is to provide a compound which is suitable for use as a material for the capping layer of an organic EL element, has a high refractive index in the wavelength range of 450-750 nm, and has a low extincti...
|
WO/2023/046698A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
WO/2023/045729A1 |
The present application relates to a nitrogen-containing compound, an electronic component comprising same, and an electronic apparatus. The nitrogen-containing compound of the present application comprises a fluorenyl group, and benzocy...
|
WO/2023/049888A1 |
The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed her...
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
WO/2023/042914A1 |
Pyrrolidine compounds having an HDAC inhibition activity which are useful for treatment or prevention of diseases involving HDACs are provided. A compound of Formula [I], or a salt thereof, wherein R1 is an optionally substituted 6- to 1...
|
WO/2023/043816A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
WO/2023/038481A1 |
The present invention relates to a heteroaryl derivative compound having STAT3 inhibitory activity, and a use thereof. The heteroaryl derivative compound according to the present invention exhibits excellent STAT3-selective inhibitory ac...
|
WO/2023/037249A1 |
The present invention discloses sulfoximines/sulfilimine containing aromatic carboxamide compounds of formula (I), Formula (I) wherein, ring-A, ring-B, ring-C, R2, R3a and R3b are as defined in the detailed description. The present inven...
|
WO/2023/036821A1 |
The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds...
|
WO/2023/033583A1 |
According to the present invention, provided are: a compound which can be applied to an electron transport layer, a hole blocking layer, or the like of an organic electroluminescent element; an organic electroluminescent element using th...
|
WO/2023/033352A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
|
WO/2023/031311A1 |
The invention provides new reversible monoacylglycerol lipase (MAGL) inhibitors that are useful for the treatment or prophylaxis of diseases or conditions associated with MAGL. The reversible MAGL inhibitors according to the present inve...
|
WO/2023/030319A1 |
An oxa-spiro small-molecule compound, a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as an MOR receptor agonist and in the preparation of a drug for treating and/or preventing dis...
|
WO/2023/031083A1 |
The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, pref...
|
WO/2023/033355A1 |
The present invention provides: a compound represented by formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode; and an...
|
WO/2023/029380A1 |
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically, disclosed are a compound as a GLP1R agonist represented by formula (I), or a pharmaceutically acceptable s...
|
WO/2023/034992A1 |
The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and...
|
WO/2023/027336A1 |
The present specification relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
WO/2023/026884A1 |
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...
|
WO/2023/028564A1 |
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and ...
|
WO/2023/026060A1 |
The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or proph...
|
WO/2023/025602A1 |
The invention relates to compounds of formula I I wherein the variables have the meanings as defined in the specification, to compositions com-prising them, to active compound combinations comprising them, and to their use for protecting...
|
WO/2023/027327A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising the compound.
|
WO/2023/027479A1 |
The present application provides: a heterocyclic compound which can significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; and an organic light-emitting d...
|
WO/2023/027173A1 |
Provided are a compound represented by formula (1) (in formula (1), N*, R1-R9, L1, L2, L3, Ar1, and Ar2 are as defined in formula (1)), an organic electroluminescent element including the compound, and an electronic device including such...
|
WO/2023/022497A1 |
Provided are a novel compound of chemical formula I and a use thereof for preventing or treating SOS1-related diseases. A novel compound according to an aspect of the present invention inhibits interaction between SOS1 and a RAS family p...
|
WO/2023/020479A1 |
The present invention relates to a compound having a PARP7 inhibitory effect as shown in formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, and use thereof and a preparation method there...
|
WO/2023/021012A1 |
Suggested are compositions comprising substituted azacycles on one hand and physiological cooling or warming agents, flavors and/or fragrances on the other for masking, enhancing and/or boosting flavors, improving soothing ability, and i...
|
WO/2023/020457A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compou...
|
WO/2023/020534A1 |
Provided herein are compounds of Formula I, II, and III, which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as ...
|
WO/2023/022233A1 |
The present invention provides: a fused ring compound which has a high glass transition temperature; a charge transport material for photoelectric conversion elements for imaging elements or a charge blocking material for photoelectric c...
|
WO/2023/022480A1 |
The present application provides: a heterocyclic compound which can significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; an organic light-emitting devic...
|
WO/2023/022417A1 |
Provided is a cyano group-substituted heteroaryl amine derivative which effectively absorbs high-energy external light source in the UV region to minimize damage to organic materials inside an organic electroluminescent device, thus cont...
|
WO/2023/016249A1 |
The present invention relates to a method for preparing a 3-aryloxy-3-five-membered heteroaryl-propylamine compound. Specifically, provided in the present invention is a method for preparing a compound of formula I. The method comprises ...
|
WO/2023/017699A1 |
The present invention addresses the problem of providing: a 3-substituted uracil compound that has excellent germicidal/antimicrobial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/h...
|
WO/2023/018052A1 |
Provided is a tertiary amine derivative, which effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials in an organic electroluminescent device, and thus contributes to a substa...
|
WO/2023/018040A1 |
Provided is a cyano group-substituted carbazole derivative, which effectively absorbs high energy external light source in a UV range so as to minimize damage to organic materials in an organic electroluminescent device, and thus contrib...
|